We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-27.88%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.32B
AUM Growth
-$346M
Cap. Flow
-$15.1M
Cap. Flow %
-1.15%
Top 10 Hldgs %
59.82%
Holding
111
New
34
Increased
24
Reduced
9
Closed
40

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$69.5M
2
ENR icon
Energizer
ENR
+$56.7M
3
SRCL
Stericycle Inc
SRCL
+$40.3M
4
SGI
Somnigroup International
SGI
+$34.7M
5
WBT
Welbilt, Inc.
WBT
+$27.1M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$37.3M
2
HOG icon
Harley-Davidson
HOG
+$37.3M
3
HBI
Hanesbrands
HBI
+$36.9M
4
CPRI icon
Capri Holdings
CPRI
+$36.7M
5
CAR icon
Avis
CAR
+$32.1M

Sector Composition

Rank Sector Weight
1 Healthcare 38.78%
2 Consumer Discretionary 11.57%
3 Industrials 7.52%
4 Consumer Staples 5.7%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
26
DELISTED
Alexion Pharmaceuticals
ALXN
$12.1M 0.92%
+124,000
New +$14.7M
ASRT
27
DELISTED
Assertio
ASRT
$11.8M 0.9%
54,633
+4,633
+9% +$1.39M
FL
28
DELISTED
Foot Locker
FL
$11.3M 0.85%
+212,000
New +$10.6M
CVS icon
29
CVS Health
CVS
$133B
$10.4M 0.78%
158,000
+58,000
+58% +$4.33M
PTCT icon
30
PTC Therapeutics
PTCT
$5.64B
$10.3M 0.78%
+300,000
New +$10.8M
PRTK
31
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.1M 0.77%
1,968,000
+768,000
+64% +$5.83M
CLLS
32
Cellectis
CLLS
$277M
$9.81M 0.74%
589,000
-11,000
-2% -$255K
SLDB icon
33
Solid Biosciences
SLDB
$794M
$8.9M 0.67%
22,133
+11,200
+102% +$5.27M
MRKR icon
34
Marker Therapeutics
MRKR
$18.8M
$8.26M 0.63%
+148,800
New +$10.8M
KPRX icon
35
Kiora Pharmaceuticals
KPRX
$11.3M
$8.03M 0.61%
3,197
+85
+3% +$196K
ATEC icon
36
Alphatec Holdings
ATEC
$1.46B
$7.64M 0.58%
3,338,414
+38,000
+1% +$107K
OLLI icon
37
Ollie's Bargain Outlet
OLLI
$4.44B
$7.18M 0.54%
+108,000
New +$8.99M
FUN icon
38
Cedar Fair
FUN
$1.77B
$7.09M 0.54%
+150,000
New +$7.83M
ACHN
39
DELISTED
Achillion Pharmaceuticals
ACHN
$6.84M 0.52%
4,300,000
+2,300,000
+115% +$6.5M
AAP icon
40
Advance Auto Parts
AAP
$3.35B
$6.61M 0.5%
+42,000
New +$7.02M
TGT icon
41
Target
TGT
$65.6B
$6.61M 0.5%
+100,000
New +$7.69M
VLRX
42
DELISTED
VALERITAS HOLDINGS INC
VLRX
$6.46M 0.49%
+992,500
New +$15.9M
INCY icon
43
Incyte
INCY
$24.2B
$6.36M 0.48%
+100,000
New +$6.49M
LRMR icon
44
Larimar Therapeutics
LRMR
$397M
$6.23M 0.47%
104,833
+7,833
+8% +$773K
FIVE icon
45
Five Below
FIVE
$12B
$6.14M 0.47%
+60,000
New +$6.63M
ADMS
46
DELISTED
Adamas Pharmaceuticals
ADMS
$5.62M 0.43%
+658,000
New +$8.56M
FRTX
47
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$5.14M 0.39%
13,843
– –
ALIM
48
DELISTED
Alimera Sciences
ALIM
$4.98M 0.38%
462,400
– –
CRSP icon
49
CRISPR Therapeutics
CRSP
$4.73B
$4.91M 0.37%
+172,000
New +$5.98M
FLXN
50
DELISTED
Flexion Therapeutics, Inc.
FLXN
$4.53M 0.34%
+400,000
New +$6.27M
1
2
3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return

Armistice Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Armistice Capital held 111 positions worth $1.32B, down 21% from $1.67B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Armistice Capital's Q4 2018 filing shows 34 new, 24 increased, 9 reduced and 40 closed positions. Its largest new stake was Energizer: 1,068,000 shares worth $48.2M. The largest sale was United Therapeutics, an estimated $37.3M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Industrials.

  • Armistice Capital's largest Q4 2018 buy was Energizer: 1,068,000 shares worth $48.2M.
  • Armistice Capital added most to Clovis Oncology, Inc. in Q4 2018, an estimated $69.5M increase.
  • Armistice Capital's biggest Q4 2018 reduction was J.M. Smucker, cutting an estimated $28.8M.
  • Armistice Capital fully exited United Therapeutics in Q4 2018, selling an estimated $37.3M.
  • Armistice Capital's ten largest holdings make up 60% of its $1.32B portfolio in Q4 2018.
  • Armistice Capital opened 34 new positions and closed 40 in Q4 2018.
  • Armistice Capital's portfolio value fell 21% quarter-over-quarter to $1.32B.

Based on Armistice Capital's 13F filing for Q4 2018, filed 14 Feb 2019.